Aspirin Contraindication in Suspected Acute Intracerebral Hemorrhage

Mandatory Neuroimaging Before Any Antiplatelet Therapy

All major stroke guideline societies (World Stroke Organization, American Heart Association/American Stroke Association, Canadian Best Practice) require definitive brain imaging to exclude intracranial hemorrhage before aspirin can be administered in any acute stroke presentation. Level A evidence. 1

A loading dose of aspirin (≈160 mg) may be given only after imaging confirms the absence of intracerebral hemorrhage. 1
Prior to oral aspirin administration, a dysphagia screening must be performed and passed to ensure safe swallowing. 3

In patients with confirmed intracerebral hemorrhage who are not scheduled for emergency neurosurgery, platelet transfusion to reverse aspirin’s antiplatelet effect is potentially harmful and should be avoided. This recommendation follows the 2022 Stroke Society guidance on ICH management. 4

Immediate non‑contrast CT or MRI is required for every patient presenting with an acute neurological deficit suggestive of stroke. 1
If imaging shows hemorrhage: aspirin is contraindicated; management should focus on blood‑pressure control and reversal of any anticoagulation, per the 2022 Stroke Society ICH guideline. 4
If imaging shows no hemorrhage (ischemic stroke confirmed): proceed to antiplatelet therapy according to stroke severity.

Minor stroke (NIHSS ≤ 3) presenting within 12–24 h: give aspirin 160–325 mg loading + clopidogrel loading (300–600 mg); continue dual antiplatelet therapy for 21 days. Class I, Level A (International Stroke Guidelines). 1
Moderate‑severe stroke (NIHSS > 3): give aspirin 160 mg loading, then continue 81–325 mg daily as monotherapy. Class I, Level A (International Stroke Guidelines). 1
If intravenous thrombolysis (tPA) was administered: delay aspirin initiation for ≥24 h and obtain a 24‑hour post‑tPA scan to exclude hemorrhagic transformation before starting any antiplatelet agent. Class I, Level B (International Stroke Guidelines). 3

The 2023 American Heart Association guideline (Class IIb, Level B‑R) states that antiplatelet agents may be considered after an ICH that was associated with prior antithrombotic use, but only in the secondary‑prevention setting weeks to months after the event. 5
The RESTART randomized trial demonstrated that restarting antiplatelet therapy after ICH did not increase recurrent ICH risk (4 % vs 9 %; adjusted HR 0.51, 95 % CI 0.25–1.03). This supports a cautious, individualized restart strategy in the chronic phase. 5

Never administer aspirin based solely on clinical suspicion of stroke without confirmed imaging exclusion of hemorrhage. 1
Never restart aspirin within 24 h after thrombolytic therapy, even if the initial scan was negative for hemorrhage. 3
Do not use platelet transfusion to reverse aspirin effect in ICH patients who are not undergoing surgery, as this may worsen outcomes. 4

The prohibition of aspirin in suspected acute intracerebral hemorrhage is supported by Level A evidence across multiple international guideline societies (World Stroke Organization, AHA/ASA, Canadian Best Practice, Stroke Society). 1